RSS   Newsletter   Contact   Advertise with us

Organovo appoints Kirk Malloy to board of directors

Staff writer | San Diego, Ca., USA | December 10, 2014
Kirk D. MalloyDecember 10, 2014, San Diego, Ca., USA - Organovo Holdings, Inc., a 3D tissue bioprinting company, announced Kirk D. Malloy has been appointed to the company's board of directors.
Dr. Malloy has held management and executive leadership positions in rapidly growing life science and diagnostics companies for 18 years. He is currently Senior Vice President and General Manager of Life Sciences at Illumina, a developer and supplier of genetic analysis instrumentation, assays and software for the life science and diagnostics markets.

At Illumina, Dr. Malloy oversees the company's core platform technologies and the core life sciences markets they enable. He joined Illumina in 2002 and has served as Vice President of Customer Solutions and Vice President of Quality.

Prior to joining Illumina, Dr. Malloy built and managed training, support and validation services at Biosite Inc., a provider of rapid diagnostics products, where he helped build the point of care cardiovascular diagnostics test market.

Before Biosite, Dr. Malloy held several commercial management positions at QIAGEN, Inc., a provider of molecular biology reagents and for the life sciences, veterinary, diagnostics, and applied markets. Before joining industry, he spent several years as an academic scientist teaching and conducting research.

Dr. Malloy earned his B.S. in biology from the University of Miami and his M.S. and Ph.D. from the University of Delaware and held post-doctoral positions at Boston University and Northeastern University. He completed a certification for Corporate Directors at UCLA Anderson School of Management.